Role of RET and BRAF genes in thyroid cancer with relevance in gene therapy treatment
1 Medicine and Nutrition Faculty Juarez University of Durango State. Durango, Dgo. México, downton aerea.
2 Genetic Department. Medicine and Nutrition, Faculty Juarez University of Durango State, Durango, Dgo., México.
Research Article
GSC Biological and Pharmaceutical Sciences, 2024, 29(02), 392–400.
Article DOI: 10.30574/gscbps.2024.29.2.0445
Publication history:
Received on 16 October 2024; revised on 25 November 2024; accepted on 27 November 2024
Abstract:
At present, cancer is a global problem, among all the types that exist, one of those that was taken into account for this research is thyroid cancer, especially associated with the predisposing genes of RET rearrangement and BRAF gene mutation, which incite the rapid exit of papillary thyroid carcinoma, from MAPK signaling pathways and conformational change by mutation in BRAF at position (V600E) and (V599E). The aim of the subsequent study is to provide recent information on the genes involved, as well as the potential impact of targeted therapies to inhibit these pathways, such as selective RET and BRAF inhibitors, providing a strategy for gene therapy and rather than the traditional approach of thyroidectomy. In addition to the way of its diagnosis by means of different genetic markers, oncogenic genes, genome sequence and generalized findings of the endocrine-genetic problem. This research also explores non-specific associations of the above-mentioned causes, generating a broader knowledge for future medical and genetic adaptation of the disease.
Keywords:
Thyroid cancer; RET rearrangement; BRAF gene mutation; Papillary thyroid carcinoma; Genetic markers; Diagnosis
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
